Leveraging Structure-Based Drug Design to Identify Next-Generation MAT2A Inhibitors, Including Brain-Penetrant and Peripherally Efficacious Leads.
Li, M., Konteatis, Z., Nagaraja, N., Chen, Y., Zhou, S., Ma, G., Gross, S., Marjon, K., Hyer, M.L., Mandley, E., Lein, M., Padyana, A.K., Jin, L., Tong, S., Peters, R., Murtie, J., Travins, J., Medeiros, M., Liu, P., Frank, V., Judd, E.T., Biller, S.A., Marks, K.M., Sui, Z., Reznik, S.K.(2022) J Med Chem 65: 4600-4615
- PubMed: 35293760 
- DOI: https://doi.org/10.1021/acs.jmedchem.1c01595
- Primary Citation of Related Structures:  
7RW5, 7RW7, 7RWG, 7RWH - PubMed Abstract: 
Inhibition of the S -adenosyl methionine (SAM)-producing metabolic enzyme, methionine adenosyltransferase 2A (MAT2A), has received significant interest in the field of medicinal chemistry due to its implication as a synthetic lethal target in cancers with the deletion of the methylthioadenosine phosphorylase (MTAP) gene ...